Sen. Tommy Tuberville Sells Eli Lilly and Company (NYSE:LLY) Stock

Senator Tommy Tuberville (R-Alabama) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on May 15th, the Senator disclosed that they had sold between $15,001 and $50,000 in Eli Lilly and Company stock on April 15th.

Senator Tommy Tuberville also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CSX (NASDAQ:CSX) on 4/15/2025.
• Sold $1,001 – $15,000 in shares of Bristol-Myers Squibb (NYSE:BMY) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of PayPal (NASDAQ:PYPL) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Constellation Brands (NYSE:STZ) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 4/15/2025.
• Purchased $50,001 – $100,000 in shares of iShares Broad USD Investment Grade Corporate Bond ETF (NASDAQ:USIG) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Mastercard (NYSE:MA) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Amgen (NASDAQ:AMGN) on 4/15/2025.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $757.23 on Friday. The stock has a fifty day simple moving average of $797.84 and a 200-day simple moving average of $805.85. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The stock has a market cap of $717.65 billion, a PE ratio of 64.67, a P/E/G ratio of 1.40 and a beta of 0.48. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter last year, the business earned $2.58 earnings per share. The business’s revenue was up 45.2% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Analyst Ratings Changes

A number of brokerages recently commented on LLY. HSBC cut Eli Lilly and Company from a “buy” rating to a “reduce” rating and lowered their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Hsbc Global Res cut Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. Truist Financial raised their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Citigroup decreased their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,011.37.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently made changes to their positions in LLY. WestEnd Advisors LLC raised its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth approximately $27,000. Citizens National Bank Trust Department increased its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company during the first quarter worth approximately $40,000. Finally, Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth approximately $43,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

About Senator Tuberville

Tommy Tuberville (Republican Party) (also known as Coach) is a member of the U.S. Senate from Alabama. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Tuberville (Republican Party) ran for election to the U.S. Senate to represent Alabama. He won in the general election on November 3, 2020. Tuberville was head coach for several college football teams between 1995 and 2016, including at Auburn University and the University of Cincinnati. Tommy Tuberville was born in Camden, Arkansas, and lives in Auburn, Alabama. Tuberville’s career experience includes working as a studio analyst with ESPN and as the head football coach of the University of Mississippi, the University of Auburn, Texas Tech University, and the University of Cincinnati.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.